atorvastatin has been researched along with Carcinoma, Ductal, Pancreatic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Astsaturov, I; Cai, KQ; Chiaverelli, R; Cukierman, E; Fang, CY; Francescone, R; Franco-Barraza, J; Gabitova-Cornell, L; Goldman, AR; Golemis, EA; Handorf, EA; Hartman, TR; Khazak, V; Moffitt, RA; Nicolas, E; O'Reilly, AM; Ogier, C; Peri, S; Restifo, D; Shah, N; Sloma, I; Surumbayeva, A; Tan, Y; Weitz, N | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Janakiram, NB; Lightfoot, S; Mohammed, A; Qian, L; Rao, CV; Steele, VE | 1 |
| Chung, YT; Li, H; Liao, J; Yan, L; Yang, AL; Yang, GY; Zhang, M; Zhang, W | 1 |
4 other study(ies) available for atorvastatin and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Animals; Atorvastatin; Biosynthetic Pathways; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cholesterol, LDL; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Mice, Inbred C57BL; Mice, Knockout; Pancreatic Neoplasms; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2020 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Disease Progression; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunoenzyme Techniques; Integrases; Interferon-Stimulated Gene Factor 3, gamma Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2012 |
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
Topics: Animals; Atorvastatin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Epoxide Hydrolases; Heptanoic Acids; Homeodomain Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Ki-67 Antigen; Mice; Pancreas; Pancreatic Neoplasms; Phosphorylation; Prenylation; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Trans-Activators; Transcriptome; Tumor Suppressor Protein p53 | 2013 |